folate receptor β

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (Ki: 6.5 nM) with antitumor activity.

EC0489 is a small molecule-drug conjugate (SMDC) that combines folic acid and desacetyl vinblastine hydrazide, serving as a high-affinity ligand for the folate receptor (FR) in refractory or metastatic tumors.

L-Serine-S2-PEG-Formic acid is a linker used in FGT-4, which acts as a TLR7 agonist and is a chimeric molecule that targets folate receptor beta (FR-β).

FGT-4 is a chimeric molecule targeting folate receptor β (FR-β) and functions as a TLR7 agonist. It enhances the secretion of iNOS and the pro-inflammatory cytokine IL-6 associated with M1 macrophages and promotes the proliferation of cytotoxic CD8+ T cells. FGT-4 demonstrates antitumor activity in the 4T1 breast cancer mouse model and is applicable for cancer immunotherapy research.